Venrock Opportunities Fund L.P. 13D and 13G filings for Viridian Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-11-14 5:53 pm Sale | 2024-09-30 | 13G | Viridian Therapeutics, Inc. VRDN | Venrock Opportunities Fund L.P. | 1,882,615 2.900% | -941,306 (-33.33%) | Filing |
| 2023-12-08 4:17 pm Purchase | 2023-11-01 | 13G | Viridian Therapeutics, Inc. VRDN | Venrock Opportunities Fund L.P. | 2,823,921 5.200% | 2,823,921 (New Position) | Filing |